Altawin

Altawin Biopharma is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, specializing in the discovery and development of innovative therapies for metabolic and autoimmune diseases. The company's lead programs focus on multi-target incretin analogs, such as GLP-1/GIP dual agonists, aimed at addressing global health challenges like obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). By leveraging its expertise in peptide engineering and metabolic signaling, Altawin aims to provide next-generation treatments with improved efficacy and safety profiles. The company is backed by prominent venture capital firms and is actively advancing its pipeline through clinical trials in China with a vision for global commercialization.